Not yet taking people in GermanyPhase 1
Immune Cell Therapy Tested in Early, Active Multiple Sclerosis
Tests an immune cell therapy in adults newly diagnosed with highly active multiple sclerosis.
Key facts
- Who runs it
- Medizinische Hochschule Hannover
- Where
- Hanover, GermanySee the site
- Trial code
- Registry title
- Immune Cell Therapy for People with Early, Active Multiple Sclerosis
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 10 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 30 Sept 2029
- Type of study
- Interventional
- Record updated
- 11 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed, highly active multiple sclerosis, to test an immune cell therapy.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Newly diagnosed, highly active multiple sclerosis
Where in Germany
- Medizinische Hochschule HannoverHanover, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Immune Cell Therapy Tested in Early, Active Multiple SclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 November 2026